Shares of “SEPN” will begin trading Friday on the Nasdaq stock exchange. GPCRs, or G protein-coupled receptors, are something of a cellular jack of all trades, involved in a range of ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024.

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor appetite for its G protein-coupled receptors (GPCRs). The South San ...